Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page’s footer version/release label was updated from v3.5.2 to v3.5.3, indicating a ClinicalTrials.gov site revision rather than any modification to the trial record.
    Difference
    0.1%
    Check dated 2026-04-24T22:44:00.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T14:13:11.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    37 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-19T23:42:05.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3. There are no apparent changes to the study content or results.
    Difference
    0.1%
    Check dated 2026-03-12T20:21:44.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2 on the page. This appears to be a minor site revision.
    Difference
    0.1%
    Check dated 2026-02-12T02:18:56.000Z thumbnail image
  7. Check
    80 days ago
    Change Detected
    Summary
    Added Revision: v3.4.1 and removed Revision: v3.4.0.
    Difference
    0.1%
    Check dated 2026-02-04T22:49:33.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.